NASDAQ:AFMD - Affimed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 261.01 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.77
▼ -0.04 (-1.42%)

This chart shows the closing price for AFMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Affimed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AFMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AFMD

Analyst Price Target is $10.00
▲ +261.01% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Affimed in the last 3 months. The average price target is $10.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 261.01% upside from the last price of $2.77.

This chart shows the closing price for AFMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Affimed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/2/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2022SVB LeerinkLower Price TargetOutperform$10.00 ➝ $9.00Low
3/30/2022Piper SandlerInitiated CoverageOverweight$7.00Low
2/23/2022Cantor FitzgeraldInitiated CoverageOverweight$12.00High
12/12/2021SVB LeerinkReiterated RatingBuyHigh
11/17/2021Berenberg BankInitiated CoverageBuyHigh
11/14/2021SVB LeerinkReiterated RatingBuy$12.00Low
10/21/2021Truist FinancialInitiated CoverageBuy$10.00Low
10/12/2021SVB LeerinkLower Price TargetOutperform$13.00 ➝ $12.00Low
9/29/2021Stifel NicolausInitiated CoverageBuy$12.00High
4/18/2021SVB LeerinkReiterated RatingBuyLow
4/12/2021BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$12.00 ➝ $15.00Medium
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$15.00High
3/24/2021Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $15.00High
3/11/2021SVB LeerinkBoost Price TargetOutperform$9.00 ➝ $14.00High
11/11/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $9.00High
8/9/2020LaidlawReiterated RatingMarket Perform ➝ Buy$10.00Medium
6/24/2020SVB LeerinkBoost Price TargetOutperform$7.00 ➝ $8.00High
4/9/2020SVB LeerinkReiterated RatingOutperformHigh
7/3/2019LaidlawSet Price TargetBuy$10.00Low
3/28/2019SVB LeerinkInitiated CoverageOutperform$8.00High
10/11/2018SunTrust BanksLower Price TargetBuy$5.00Low
8/28/2018Jefferies Financial GroupUpgradeHold ➝ Buy$1.80 ➝ $4.00High
8/28/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.00High
8/9/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$6.00 ➝ $4.00High
11/24/2017OppenheimerReiterated RatingHoldLow
7/27/2017Jefferies Financial GroupReiterated RatingHold$2.50Low
7/13/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$7.00High
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
12/3/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/1/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/3/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/2/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/2/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
6/1/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/1/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Affimed logo
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More

Today's Range

Now: $2.77
Low: $2.70
High: $2.80

50 Day Range

MA: $3.13
Low: $2.27
High: $4.06

52 Week Range

Now: $2.77
Low: $2.23
High: $7.99

Volume

652,348 shs

Average Volume

1,541,162 shs

Market Capitalization

$341.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Affimed?

The following sell-side analysts have issued stock ratings on Affimed in the last twelve months: Berenberg Bank, Cantor Fitzgerald, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for AFMD.

What is the current price target for Affimed?

0 Wall Street analysts have set twelve-month price targets for Affimed in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 261.0%.
View the latest price targets for AFMD.

What is the current consensus analyst rating for Affimed?

Affimed currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AFMD will outperform the market and that investors should add to their positions of Affimed.
View the latest ratings for AFMD.

How do I contact Affimed's investor relations team?

Affimed's physical mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company's listed phone number is 496221674360 and its investor relations email address is [email protected] The official website for Affimed is www.affimed.com. Learn More about contacing Affimed investor relations.